Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort
Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort have?
Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort has 31 citations in the OpenAlex counts ScholarIQ stores.
When was Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort published?
Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort has 2020 year in the ScholarIQ index.
What is the open-access status of Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort?
Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort has gold oa status in the ScholarIQ index.
What is the DOI of Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort?
The DOI for Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort is on the source record.
What is the PMID of Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort?
The PMID for Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort is on the source record.
What is the OpenAlex record for Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort?
The OpenAlex for Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort is on the source record.